Medical debulking with BRAF/MEK inhibitors in aggressive <i>BRAF</i>-mutant craniopharyngioma
Anna Luisa Di Stefano(Hôpital Foch), S. Gaillard(Hôpital Foch), V. Desforges Bullet(Centre Hospitalier de Versailles), Chiara Villa(Centre National de la Recherche Scientifique), David Guyon(Centre National de la Recherche Scientifique), Karine Sejean(Hôpital Foch), Emmanuel Halimi(Hôpital Foch), L. Feuvret(Sorbonne Université), Bertrand Baussart(Centre National de la Recherche Scientifique), A. Boulin(Fondation de Rothschild), Giulia Berzero(Sorbonne Université)
Cited by 23
Related Papers
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
|The Lancet Oncology|2016|504
Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors
|Nature Genetics|2017|381
Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line<i>AIP</i>Mutations and Pituitary Adenomas: An International Collaborative Study
|The Journal of Clinical Endocrinology & Metabolism|2010|374
From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal
|Endocrine Related Cancer|2017|357
Gigantism and Acromegaly Due to Xq26 Microduplications and <i>GPR101</i> Mutation
|New England Journal of Medicine|2014|340